Alnylam Pharmaceuticals Overview
Alnylam Pharmaceuticals (0HD2.L) has a ROE of 59.67%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow59.67%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 0HD2.L is 59.67%. That is above the Healthcare sector average of -100.59%. Investors often review this figure alongside Alnylam Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, 0HD2.L currently prints 59.67% for ROE, while the sector average sits near -100.59%. That is roughly 159.3% above the sector mean. Large gaps often invite a closer look at Alnylam Pharmaceuticals's growth, margins, and balance sheet.
Return on Equity shows how effectively Alnylam Pharmaceuticals converts resources into returns. At 59.67%, 0HD2.L may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 0HD2.L's ROE (59.67%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Alnylam Pharmaceuticals's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
